2-methyl-5-(2-[N-nitroso-(2-methylphenyl)amino]ethyl)pyridine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-5-(2-[N-nitroso-(2-methylphenyl)amino]ethyl)pyridine
• 英文别名: N-(2-methylphenyl)-N-[2-(6-methylpyridin-3-yl)ethyl]nitrous amide
• 化学式: C₁₅H₁₇N₃O
• 分子量: 255.319
• InChiKey: XVNVNDLKZQGDDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-methyl-5-(2-[N-nitroso-(2-methylphenyl)amino]ethyl)pyridine 在 盐酸 、 水 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 38.0h， 生成 2,3,4,5-四氢-2,8-二甲基-5-[2-(6-甲基吡啶-3-基)乙基]-1H-吡啶并[4,3-b]吲哚
  参考文献：
  名称：

  SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO [4, 3-B]INDOLE DERIVATIVE

  摘要：

  公开号：

  EP2417973B1

文献信息

• Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives
  申请人：Li Song

  公开号：US20120122914A1

  公开（公告）日：2012-05-17

  The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.

  本发明涉及一种缓释组合物，其包含2,3,4,5-四氢-2,8-二甲基-5-[2-(6-甲基-3-吡啶基)乙基]-1H-吡啶并[4,3-b]吲哚或其药学上可接受的盐作为活性成分，以及其制备方法和该化合物。该组合物适用于每天一次口服，口服后1.0至3小时达到峰值血浆浓度。该组合物适用于制造治疗认知功能障碍综合征、阿尔茨海默病、帕金森病、亨廷顿病或老年性痴呆的药物。
• SYNTHESIS OF 9-(ARYLALKYL)-1,2,3,4-TETRAHYDRO-y-CARBOLINE AND ANALOGUES AND INTERMEDIATES
  申请人：Williamson Craig

  公开号：US20110245504A1

  公开（公告）日：2011-10-06

  The present invention pertains generally to methods of preparing certain 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline compounds and their analogues, and especially to methods of preparing dimebon. The present invention also pertains to methods of preparing certain intermediate compounds which find use in the synthesis of the 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline compounds.

  本发明涉及制备某些9-(芳基烷基)-1,2,3,4-四氢-γ-咔啉化合物及其类似物的方法，特别是制备地美莫辛的方法。本发明还涉及制备某些中间化合物的方法，这些中间化合物在合成9-(芳基烷基)-1,2,3,4-四氢-γ-咔啉化合物时有用。
• SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO Ý4, 3-b¨INDOLE DERIVATIVE AND PREPARATION METHOD OF DERIVATIVE
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A.

  公开号：EP2417973A1

  公开（公告）日：2012-02-15

  The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.

  本发明涉及一种含有 2,3,4,5-四氢-2,8-二甲基-5-[2-(6-甲基-3-吡啶基)乙基]-1H-吡啶并[4,3-b]吲哚或其药学上可接受的盐作为活性成分的缓释组合物、其制备方法和化合物。该组合物适合每天口服一次，并在口服后 1.0 至 3 小时达到血浆峰值浓度。该组合物适用于制造治疗认知功能障碍综合征、阿尔茨海默病、帕金森病、亨廷顿病或老年痴呆症的药物。
• Preparation of tetrahydropyrido[4,3-b]indole derivatives
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

  公开号：EP2581374A1

  公开（公告）日：2013-04-17

  The present invention relates to the preparation of 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole.

  本发明涉及 2,3,4,5-四氢-2,8-二甲基-5-[2-(6-甲基-3-吡啶基)乙基]-1H-吡啶并[4,3-b]吲哚的制备。
• US8703952B2
  申请人：——

  公开号：US8703952B2

  公开（公告）日：2014-04-22